Navigation Links
CORD:USE Cord Blood Bank Announces the Addition of Dr. John Wagner, a Pioneer in the Use of Umbilical Cord Blood Stem Cells, to Its Scientific Advisory Board
Date:1/30/2008

ORLANDO, Fla., Jan. 30 /PRNewswire/ -- John Wagner, M.D., recognized as a leader in the field of cord blood stem cell transplantation, has joined the team at CORD:USE Cord Blood Bank. Dr. Wagner's extensive experience and knowledge in transplant medicine and stem cell biology will provide a significant contribution to CORD:USE.

"We're honored and fortunate to have him as a member of our distinguished team," says Edward Guindi, M.D., President and CEO of CORD:USE Cord Blood Bank.

Dr. Wagner is internationally recognized as an expert in the field of stem cells and use of unrelated hematopoietic stem cell transplant. He is a professor of Pediatrics and the Director of the Division of Hematology- Oncology and Blood and Marrow Transplantation at the University of Minnesota. He is also the Scientific Director of Clinical Research of the Stem Cell Institute and Director of the Center of Molecular and Cellular Therapeutics.

Dr. Wagner has played a considerable role in the development and expansion of the applications of cord blood stem cells. His investigations on the simultaneous use of two cord blood units for transplantation in adults has made it possible for nearly all patients to benefit from cord blood stem cell transplantation who otherwise would not have been candidates for this therapy.

"Without question, I look forward to working with such a distinguished board of scientific advisors and the impressive team at CORD:USE," says Dr. Wagner. "Cord blood stem cells have already played an extremely important role in the treatment of thousands of patients, and I foresee the uses of cord blood expanding, such as in the field of regenerative medicine and tissue repair. The experience and expertise of the team at CORD:USE will help ensure that CORD:USE remains a leader in the field."

Dr. Wagner joins other highly-respected leaders in the field of cord blood stem cell transplantation at CORD:USE. Dr. Joanne Kurtzberg is the Director of the Pediatric Blood and Marrow Program at Duke University and the Medical Director of the CORD:USE Cord Blood Bank at Duke. She performed the first transplantation using an unrelated donor's stem cells and has since performed over 800 umbilical cord blood transplants.

Dr. Wagner also joins Dr. Hal Broxmeyer, a founder of the field of cord blood stem cell transplantation and widely recognized as one of the foremost experts in the world in cord blood stem cell science. Also on the CORD:USE team is Dr. Alan Levine, who serves as the company's Chief Scientific Officer. Dr. Levine enjoyed a highly successful 25-year career with the National Institutes of Health ("NIH") where he was most recently the Director of the Blood Disease Program of the National Heart, Lung, and Blood Institute of the NIH. In this capacity, Dr. Levine was responsible for initiating the bone marrow and umbilical cord blood research programs at the NIH.

Dr. Levine works closely with CORD:USE team member Dr. Esmail Zanjani, a world-renowned expert in blood stem cell biology who has led the development of the field of in utero stem cell transplantation and gene therapy as a means for curing genetic diseases prior to birth.

About CORD:USE Cord Blood Bank, Inc.

CORD:USE Cord Blood Bank, headquartered in Orlando, Florida, is creating a large, ethnically diverse, high quality inventory of available cord blood stem cell units for the many patients in need of a potentially life-saving transplant. Cord blood stem cells have been used successfully in the treatment of over 70 blood cancers and diseases. CORD:USE Cord Blood Bank has entered into agreements with hospitals across the country to provide mothers the option to donate their babies' cord blood. CORD:USE distributes cord blood units to transplanters, throughout the country and the world, as a critical component in their patients' treatment. CORD:USE lists all of its units on the National Marrow Donor Program's Registry. For more information, please visit our Web site http://www.corduse.com or contact Michael Ernst at 407-667- 4844 or by e-mail at mernst@corduse.com.


'/>"/>
SOURCE CORD:USE Cord Blood Bank, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
2. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
3. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
4. The International Diabetes Federation (IDF) Recommends Tighter Control of Blood Glucose Levels After Meals in People With Diabetes
5. CDC Awards NATT Funding to Improve Blood Clot Awareness
6. FDA Clears OmniWave(TM) Endovascular System for Clot Removal in Peripheral Blood Vessels
7. Cellestis Receives FDA Approval for Blood Test for Detecting Tuberculosis
8. Blood Donations in U.S. Testing Positive for Chagas Disease
9. One of Nations Oldest Blood Services Providers Turns to Sysmex America
10. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
11. AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017  OncoSec Medical Incorporated ... immunotherapies, will host a Key Opinion Leader event to ... an oral and poster presentation at the upcoming 2017 ... The KOL event will be held in-person and via ... EST / 9:00 AM PST at the Lotte New ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017  MIODx ... license for two key immunotherapy technologies from the ... technology provides a method to monitor a patient ... as PD-L1 and CTLA-4.  The second license extends ... a patient is likely to have an immune-related ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... that in a published evaluation of multiple immunoassay-based threat detection technologies by ... Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found to have ...
(Date:2/23/2017)... Feb. 23, 2017 Aviva Systems Biology ... the acquisition of GenWay Biotech Incorporated, a protein ... and product offering for both the research and ... growth and enhance capabilities for both entities. GenWay,s 18 ... assays will nicely complement ASB,s objective to become ...
Breaking Biology Technology:
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
(Date:2/8/2017)... YORK , Feb. 7, 2017 Report Highlights ... The ... should reach $11.4 billion by 2021, growing at a compound ... Includes - An overview of the global markets for synthetic ... 2015, estimates for 2016, and projections of compound annual growth ...
(Date:2/7/2017)... Ind. , Feb. 7, 2017 Zimmer ... leader in musculoskeletal healthcare, will present at the LEERINK ... New York Palace Hotel on Wednesday, February 15, 2017 ... live webcast of the presentation can be accessed at ... replay following the conference via Zimmer Biomet,s Investor Relations ...
Breaking Biology News(10 mins):